Anteris Technologies Global Corp. (AVR)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$5.58-8.82%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · AVR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 107.8% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 29 industry peers
AVR — CFO transition
Dated 2026-09-08
CFO — Brent Moen: The filing announces the appointment of an external candidate as Chief Financial Officer, which is a significant management addition but not a departure.
Why it matters: The health sector has been a tailwind, but AVR's signals remain weak and its risk label is elevated. Trial progress matters more than broad sector strength.
Watch forThe Nov. 11 update reports more active trial sites and patient enrollment across the U.S. and Europe.
Also watch forThe update reports fewer active sites, slow enrollment, or a delay to trial work.
Why it matters: The trial needs about 1,000 patients to test DurAVR against approved valves. Slow enrollment could delay this key test.
Worry ifAnteris reports enrollment near or at the planned 1,000 patients, with no major change to the trial plan.
Less concerning ifEnrollment stays far below 1,000, or Anteris reports a trial delay or a smaller study.
Why it matters: Anteris is funding a large trial and building manufacturing capacity. Lower cash use may ease funding pressure; a sharp rise may add to it.
Watch forQ3 net operating cash outflow is below $20.8 million, the Q2 level, while trial work continues.
Also watch forQ3 net operating cash outflow is above $28.7 million, the Q1 level.
Why it matters: Medicare coverage is in place, and U.S. recruitment has begun. More patients would show that sites are using this support.
Supportive ifThe next update reports rising U.S. patient enrollment and more active U.S. sites.
Worry ifThe next update reports no new U.S. patients or delayed site openings.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$229 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $558 loss on $10,000 · 5.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,702 loss on $10,000 · 47.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Anteris extended its supply deal with Harvey. Clear supply plans would support manufacturing; a short deal or supply issue could slow it.
Watch forA filing or company update confirms the extended deal is still in force. It reports no supply interruption.
Also watch forAnteris reports a supply problem, a dispute with Harvey, or an end to the agreement.